KR100982064B1 - Monoclonal antibody and diagnostic method of malaria parasites - Google Patents

Abstract

The present invention relates to a method for producing a monoclonal antibody using malaria dehydrogenase Polypeptide and a method for diagnosing malaria using the same. Specifically, a tropical fever using a polypeptide encoding an LDH gene of malaria is used. Specific monoclonal antibodies against malaria specific antigens (PfMSP, PfLDH, PfHRP), trifluid malaria specific antigens (PvMSP, PvLDH, PvHRP) and antigenic determinants were prepared to confirm their sensitivity to diagnose malaria patients and prevent malaria Or it can be widely applied to therapeutic development.

Malaria, monoclonal antibody, febrile malaria, tropical malaria, diagnostic method

Description

      Monoclonal antibody against malaria protozoa and method for diagnosing malaria using same

1 is a diagram showing the amino acid sequence of LDH isolated from tropical malaria,

2 is a diagram measuring the antibody titers of mice immunized with PfLDH # 2, a febrile malaria recombinant antigen protein,

3 is a diagram measuring the antibody titers of mice immunized with PfLDH # 3, a tropical fever malaria recombinant antigen protein,

Figure 4 is a measure of the absorbance of the supernatant of the medium in which hybrid cells secreting monoclonal antibody against PfLDH # 2,

FIG. 5 is a diagram showing the absorbance of the supernatant of the culture medium in which hybrid cells secreting monoclonal antibody against PfLDH # 3 are grown.

6 is a diagram measuring the absorbance of a monoclonal antibody against PfLDH # 2 obtained by the mouse ascites collection method,

7 is a diagram measuring the absorbance of a monoclonal antibody against PfLDH # 3 obtained by the mouse ascites collection method,

8 is a diagram showing the size of the LDH moiety in the lysate (merozoites lysate) of the tropical fever malaria merozole with M (size marker),

9 is a diagram showing whether monoclonal antibodies against PfLDH # 2 (B4D, C2B, D2H, D7E) react with the LDH antigen of malaria,

10 is a diagram showing whether monoclonal antibodies (A4F, A7E, B9G, D5G) against PfLDH # 3 react with LDH antigen of malaria,

11 is a diagram showing whether the reaction with monoclonal antibody (D7E) after diluting the tropic malaria mesozoite lysate to see the sensitivity of the monoclonal antibody (D7E) to PfLDH # 2,

12 is a diagram showing whether the reaction with the monoclonal antibody (D5G) after diluting the tropic malaria mesozoite lysate to see the sensitivity of the monoclonal antibody (D5G) to PfLDH # 3.

The present invention relates to the production of monoclonal antibodies that react with LDH (Lactate Dehydrogenase) of malaria and a method for diagnosing highly sensitive malaria using the same.

Malaria is caused by protozoan parasites of the genus Plasmodium. Four species that infect humans include P. falciparum (tropical malaria), P. vivax ( triple malaria), P. malariae and Plasmodium ovary. There is a ballet ( P. ovale ). Of these, Plasmodium falciparum mainly causes acute malaria and often fatal malaria, but the morbidity associated with each malaria infection is significant and most of the world's population is at risk of developing the disease. Malaria is a public health problem in areas where 40% of the world's population lives, and the disease has serious social and economic consequences for these communities. The disease has recently been revived by the abandonment or collapse of regulatory measures and the increased resistance of the vector to insecticides and falciparum malaria for chemotherapy. Therefore, it is urgent to develop effective vaccines against malaria.

Most experiments to develop vaccines have focused on identifying one protein that can induce a protective immune response in the host against the species and stages of the parasite involved. This is a tremendous task in itself due to the superficial understanding of the complexity of the parasite's life cycle, the number and diversity of antigens within the scope of the synthesized polypeptide, and important aspects of the immune system that regulate malaria. Nevertheless, some proteins have been identified by using antibodies against fragments of genes expressed from monoclonal antibodies, serum from immune individuals and libraries in bacteria. Several vaccine candidates have been proposed by using a number of standards, including the effect of antibodies in vitro or in vivo on the growth and development of parasites, direct immune experiments, and subcellular location or possible function of proteins. . One of the candidates is abbreviated as merozoite surface protein-1 (MSP-1) located outside of the merozoite, a parasite stage that invades red blood cells, but is also known as MSAI, PMMSA, P. 190 or gP 195. Yes). MSP1 is an ideal target for candidate malaria vaccines because it is found on the merozite surface of all malaria parasites. Indeed, the precursor protein is hydrolyzed to form complexes of several polypeptides of different molecular weights (Holder et al., Parasitology , 94 , pp. 199-208, 1987).

Malaria is the five major diseases designated by the World Health Organization (WHO) and is a fatal disease with 500,000 deaths worldwide in one year. Malaria diagnosis is based on the thin smear method and the thick smear method using peripheral blood (peripheral blood). The dyeing method commonly used in this method is the Light-Giemsa dyeing method, which requires a lot of time, and even an experienced skilled person is likely to make a mistake.

Molecular biological methods are published by Rubio et al. (Rubio JM, Garcia L. et al., Usefulness of seminested multiplex PCR in surveillance of imported malaria in Spain, J Clin Microbiol , 37 (10) , pp3260-3264, 1999). Malaria detection using polymerase reaction of protozoal DNA is mainly used. Genetic testing (Nested-PCR) is mainly used, and the target gene amplifies the circumsporozoite protein gene, merozoite surface protein gene, and red blood cell binding protein gene. PCR is also applied to follow-up of malaria because of its high sensitivity, but it is difficult to quantify blood levels of malaria (Pieroni P. et al., Comparison of the ParaSight-F test and the ICT Malaria Pf test with the polymerase chain reaction for the diagnosis of Plasmodium falciparum malaria in travelers, Trans R Soc Trop Med Hyg , 92 (2) , pp. 166-169, 1998).

As such, the existing diagnostic methods have disadvantages and limitations. In addition, Korea's three-day malaria ( Plamodium vivax ) shows a short incubation period of less than one month, but usually has a long incubation period of six months to one year, longer than three years. This prolonged incubation type is difficult to diagnose because the antibody is not formed or the amount of antigen is very small and may appear asymptomatic. Therefore, it must be diagnosed early. In addition, malaria fever is not only an unresolved infectious disease in Korea, China, Southeast Asia, and South America, but can also be transmitted through blood transfusions, and is a disease that requires screening of blood.

Currently, the most widely used method in the world is the dipstick kit method. Plasmodium lactate dehydrogenase (pLDH) and Plasmodium histidine rich protein-2 among specific antigens of malaria pHRP-2) A method for detecting an antigen. These products were commercialized using ICTTM Malaria Pf / Pv (Amrad ICT, Australia), OptiMAL (Flow Inc., USA), and ParaSightTM F (Becton Dickinson, USA). Compliment products from these three companies (Chansuda W, Rapid diagnostic techniques for malaria control, Trends Parasitol , 17 (7) , pp307-309, 2001) showed that tropical fever malaria ( Plasmodium) falciparum ) has a high diagnostic sensitivity of 88-98%, whereas Plasmodium vivax ) had problems with 75%, 83% and 87%, respectively. Contrary to the insistence of the product supplier, supplementation is necessary because the sensitivity is lower than conventional methods, and the diagnosis rate of trine malaria is only 70-80% (Cooke AH. Et al., Comparison of a parasite lactate dehydrogenase-). based immunochromatographic antigen detection assay (OptiMAL) with microscopy for the detection of malaria parasites in human blood samples, Am J Trop Med Hyg , 60 (2) , pp 173-176, 1999). One reason for this is that in developed countries, mainly research on tropical malaria has been undertaken, and relatively less than three days of malaria. Due to the limitations of pure culture and regional differences in protozoa, there have been limitations in the study, diagnosis and treatment of triple fever malaria (Moody A., Rapid diagnostic tests for malaria parasites, Clin Microbiol Rev , 15 (1) , pp 66-78, 2002). As yet, no highly sensitive antibodies have been developed for diagnosing triplet malaria and tropical malaria, which are widely distributed in Southeast Asia and Latin America, including Korea.

In general, the antigenic structure of protozoa is complex, making it difficult to analyze individual antigens and antigenic determinants. To this end, a monoclonal antibody is produced using the cell fusion technique, which is still widely used, and studies on antigen structure and antigen determinants (Kohler G. et al., Continuous cultures) of fused cells secreting antibody of predefined specificity, Nature , 256 (5517) , pp 495-7496, 1975).

Malaria lactate dehydrogenase is a metabolic enzyme found in the protoplasm of the protozoa. It affects the metabolism of protozoa and is present at all stages of malaria. In this case, it is possible to produce antibodies specific for lactic acid dehydrogenase of tropical malaria and antibodies common to lactic acid dehydrogenase of other malaria protozoa when preparing antibodies thereto.

Accordingly, the present inventors primarily intended to prepare specific monoclonal antibodies against tropical fever malaria (PfMSP, PfLDH, PfHRP), triplet malaria specific antigen (PvMSP, PvLDH, PvHRP) and antigenic determinants, LDH of tropical fever malaria Monoclonal antibodies were produced and characterized using polypeptides encoding genes, and production of monoclonal antibodies against specific antigens and antigenic determinants resulted in diagnostic sensitivity in diagnosing febrile and febrile malaria patients. It was confirmed that can be increased to complete the present invention.

An object of the present invention is to provide a monoclonal antibody that reacts with LDH (Lactate Dehydrogenase) of malaria and to provide a method for diagnosing highly sensitive malaria using the same.

In accordance with the above object, the present invention provides a monoclonal antibody that reacts with LDH (Lactate Dehydrogenase) of malaria and a method for diagnosing highly sensitive malaria using the same.

In detail, the method provides a method for producing a monoclonal antibody by preparing a malaria-specific site in a gene encoding a lactate dehydrogenase (LDH) from a malaria parasite as a peptide.

Hereinafter, the present invention will be described in detail.

To prepare a monoclonal antibody from a region of the gene coding for lactate dehydrogenase (LDH) from malaria protozoa, the antigenicity of which is expected to be specific for tropical and tritidal malaria 1) Peptides for specific portions of the LDH gene Preparing and attaching MAPs as carriers to immunize the peptide antigen with mice; 2) separating serum from the immunized mouse and performing cell fusion with myeloma cells; 3) selecting a hybrid cell (hybridoma cell) using HAT (hypoxantine, aminopterin, thymidine) medium from the fusion cell, and separating and culturing the antibody to confirm antibody secretion; 4) selecting monoclonal cell lines producing monoclonal antibodies from the hybrid cells using limiting dilution; 5) The monoclonal antibody of the present invention can be obtained by culturing the monoclonal cell line in a large amount and purely separating the monoclonal antibody using protein A affinity chromatography.

In addition, the monoclonal antibody of the present invention is performed in the same manner to the step 3) in the monoclonal antibody acquisition method consisting of the above five steps, 4) the mouse intraperitoneally (pristane) or IFA (incomplete freund's adjuvant) intraperitoneally Injecting the fusion cells intraperitoneally 7 to 10 days after injection; 5) 1 to 2 weeks after the injection of the fusion cells, if the ascites fills the abdominal cavity, puncture the ascites with a needle, collect the centrifugal precipitate, and collect the supernatant; 6) The supernatant may be further subjected to the pure separation of the antibody using a Protein A column to obtain a monoclonal antibody of the present invention.

Antigens prepared from the peptides of the invention are characterized in that they are selected from SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, the monoclonal antibodies obtained in the present invention are B4D, C2B, D2H and D7E, A4F, A7E, B9G and D5G antibodies obtained from the antigen of SEQ ID NO: 3.

As a result of confirming the isotype of the monoclonal antibody of the present invention, the monoclonal antibody against the antigen of SEQ ID NO: 2 is of IgM class, and the monoclonal antibody against the antigen of SEQ ID NO: 3 is of IgG2b class (class). It was confirmed).

Furthermore, the Plasmodium of the invention plasminogen modium arm Shifa room (P. falciparum), non-plasminogen modium box (P. vivax), plasminogen modium malaria (P. malariae) and flasks modium Ovalle (P. ovale), preferably It comprises a plastic arm modium Shifa room (P. falciparum) and non-plastic modium box (P. vivax).

The present invention provides a diagnostic method for diagnosing malaria disease using a monoclonal antibody prepared by the above method.

The monoclonal antibody is characterized by using a monoclonal antibody common to lactic acid dehydrogenase (LDH) of tropical fever malaria and triplet malaria.

In addition, the monoclonal antibodies of the present invention can be used in methods for evaluating therapeutic agents for the prevention or treatment of malaria.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

Example  One. Tropical heat  Malaria Antigen Preparation and Immunity in Mice

1-1. Tropical heat  Malaria antigen BALB / c immunization in mice

First six primary BALB / c mouse falciparum shown in Figure 1 creates a group to each of 3 rats (18g, female) malaria (Plasmodium Lactate dehydrogenase gene of falciparum ) and recombinant proteins for the reactive # 1 # 2 and # 3 parts (see FIG. 1) were synthesized to prepare antigens for specific parts. Since the size of each recombinant protein is small and does not show immunity, a recombinant protein antigen (Hapten-Carrier conjugate) having immunity was constructed as shown in Table 1 and SEQ ID NOs: 1 to 3 by linking carriers. Immunized with the highest biologically responsive antigens (named PfLDH # 1, PfLDH # 2 and PfLDH # 3, respectively) of the malaria antigens produced. At this time, 200 μl of the antigen (protein content of 50 μg) was mixed well with the same amount of adjuvant (Freund's complete adjuvant) and injected into the mouse abdominal cavity. From the second time, two weeks apart, the same amount of antigen was mixed with Freund's incomplete adjuvant and immunized intraperitoneally. After three immunizations, two weeks after the last immunization, when the immuno titer was measured by ELISA method and showed a value of 1: 50,000 or more, 100 μl of antigen (25 μg of protein content) was added to the tail of the mouse. Intravenously. After 4-6 days, spleen cells of the mice were extracted and used for cell fusion with SP2 / 0 Myeloma cells.

Unusual Amino acid sequence (recombinant protein antigen) Antigen name Sequence length #One -SKAKIVLVGSGMIGGVMATLIVGKNL- PfLDH # 1 26 amino acids #2 -FTKAPGKSDKEWNRDDLLPLNNKIMIEIGGH- PfLDH # 2 31 amino acids # 3 -DYG-HSDIFGGTPVVLGAN- PfLDH # 3 18 amino acids

1-2. Immunized with malaria antigen BALB / c mouse antibodies measured

Mice were immunized with recombinant antigen peptides (PfLDH # 1, PfLDH # 2, and PfLDH # 3) against the LDH gene of tropic malaria, and then immunodirectivities were confirmed by indirect ELISA. Analysis of the serum of mice obtained after the second immunization confirmed that the absorbance of mouse serum immunized with PfLDH # 2 was 0.67. In the same way, the serum of mice obtained after the 4th immunization showed a value of 1.34. The final result after intravenous injection was 1.4. 0.25 and 0.18 were shown in normal mice that were immune to nothing and negative controls that were tested with PBS. In addition, the absorbance of mouse serum immunized with PfLDH # 3 was found to be 0.52. In the same way, a value of 0.95 was found in the serum of mice obtained after the fourth immunization. The final result after intravenous injection was 1.1. Normal mice that were immune to nothing and negative controls tested with PBS showed 0.15 and 0.1, respectively (see FIGS. 2 and 3).

The results of FIGS. 2 and 3 show the results of analysis of the serum of mice obtained after immunization with recombinant antigenic proteins for tropical malaria # 2 and # 3. Finally, in this experiment, ELISA measurements showed cell fusion with mice with absorbance greater than 0.8.

Example  2. Cell fusion ( cell fusion ) And hybrid cells ( hybridoma cell ) Production

The antigen was immunized to the mouse according to the plan, blood was collected from the tail of the mouse, and immuno titer was confirmed by immunoassay adsorption (ELISA). Spleens from mice with a titer of at least 1: 100,000 were isolated and splenocytes isolated from RPMI-1640 medium, followed by myeloma cells (SP2 / 0 cell line, ATCC) grown in RPMI-1640 medium (containing 10% fetal bovine serum). Cell fusion was performed (Kohler G et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature , 256 (5517) , pp 495-497, 1975).

CO ₂ Hybrid cells in which cell fusion occurred in a thermostat (37 ° C., 5% CO ₂ ) were selected, isolated and cultured using HAT (hypoxantine, aminopterine, thymidine) medium, and antibody secretion was observed by ELISA. Cells of wells that secrete antibodies were selected and separated and cultured using HT (hypoxantine, thymidine) medium. The growth of hybrid cells was observed with an inverted microscope.

After several cell fusions, the approximate cell fusion rate was about 90% in PfLDH # 2 and about 60% in PfLDH # 3. However, no hybrid cell line for PfLDH # 1 was obtained. Finally, 16 hybrid cell lines specific for PfLDH # 2 and 14 hybrid cell lines specific for PfLDH # 3 were obtained, and three monoclonal cell lines for PfLDH # 2 and PfLDH # 3 were subjected to three limiting dilutions. Four monoclonal cell lines were finally selected. The ELISA measured the absorbance of four monoclonal antibodies against PfLDH # 2 and four monoclonal antibodies against PfLDH # 3, with high values between 1.75 and 2.53 for monoclonal antibodies against PfLDH # 2. Monoclonal antibodies to PfLDH # 3 showed values between 1.05 and 1.7 (see FIGS. 4 and 5).

In all experiments, ELISA was performed three times, respectively, and measured using the supernatant of monoclonal cell lines incubated for three days. The monoclonal antibodies against PfLDH # 2 were named B4D, C2B, D2H and D7E, and the monoclonal antibodies against PfLDH # 3 were named A4F, A7E, B9G and D5G. Also, among the monoclonal antibodies against PfLDH # 2, D7E showed the highest titers among the monoclonal antibodies against PfLDH # 3.

In order to obtain a large amount of antibodies, a method of harvesting ascites generated by injecting each hybrid cell into the abdominal cavity of the mouse was performed. In order to measure the titer of the antibody obtained through this method, the ascites collected from the mice were diluted in a phosphate buffer solution (PBS) at a concentration of 1:50 and subjected to ELISA. As a result of three repeated experiments, the absorbance values obtained from the monoclonal antibody against PfLDH # 2 ranged from 1.43 to 2.05, and are shown in FIG. 6, and the absorbance values obtained from the monoclonal antibody against PfLDH # 3. In the range from 0.92 to 1.35, it is shown in FIG. 7.

This experiment confirmed that the concentration of the antibody secreted in the ascites of the mouse is 50 times more than the antibody obtained through the culture of the monoclonal cell line. Antibodies were isolated and purified from mouse ascites using Protein A column affinity chromatography, and the obtained antibodies were stored at -20 ° C.

Example  3. Immunoenzyme adsorption ELISA Enforcement

In order to confirm the titer of immunized mice and antibody production of fusion cells, immunoassay adsorption (ELISA) was performed. Each antigen was diluted in 0.05M buffer solution (pH 9.6, carbonate-bicarbonate buffer solution) to a protein concentration of 1-5 μg / ml, and 100 μl / well in polystyrene ELISA plates (Immunoplate, Nunc). After dispensing, the antigens were attached for at least 12 hours at 4 ° C. The ELISA plate to which the antigen was attached was washed three times with PBST (phosphate buffer solution containing 0.05% Tween 20, pH7.4) three times for 5 minutes, and then reacted with 3% BSA at 37 ° C for 1 hour to block nonspecific reactions. The serum to be tested was diluted 1: 100-1: 500 in 0.01M PBS (pH 7.4) and reacted at 37 ° C. for at least 1 hour, washed three times with PBST for 5 minutes, and then in 0.01M PBS (pH 7.4). : Immunoglobulin (peroxidase conjugated goat anti-mouse immunoglobulin, Cappel, USA) diluted to 3,000-1: 5,000 was added to 100 μl / well and reacted at 37 ° C. for 1 hour.

After washing three times with PBST for 5 minutes, dissolve one p -NPP tablet ( p -nitrophenyl phosphate 20mg, Sigma) in 10ml of substrate buffer solution, add 100 ul / well of the solution and block the light at room temperature. After reacting for 30 minutes, the absorbance of each well was measured at a wavelength of 405 nm with an ELISA reader.

Example  4. Selection of cell populations producing monoclonal antibodies

The selection of monoclonals to produce monoclonal antibodies was selected using limiting dilution. That is, in order to select the cells producing the antibody among the hybrid cells in culture, 96-well plates were examined by ELISA, and only the wells producing the antibody were transferred to 24-well plates and cultured. The number of cells grown was calculated to be 0.25 cells / well in a 96-well plate, put into a 96-well plate and incubated.

The wells in which the cells were grown were selected to confirm the production of the antibodies by the ELISA method, and the wells secreting the antibodies were selected and cultured in 24-well plates. This method was repeated 2-3 times to select monoclonal cell lines.

Example  5. Isotyping monoclonal antibodies isotyping )

In order to confirm the isotype of the secreted antibody, an isotype was performed using an isotyping kit (Sigma mouse monoclonal antibody isotyping kit, ISO-1, Sigma).

Isotyping of the obtained monoclonal antibodies was carried out using a kit (Sigma mouse monoclonal antibody isotyping kit). As a result, monoclonal antibodies against PfLDH # 2 were all clones of the IgM class. All four clones were identified as IgG2b class.

Example  6. Mass Production and Purification of Monoclonal Antibodies

Monoclonal cell lines secreting antibodies were incubated in large quantities and only single cell population antibodies were isolated from the cultures using protein A column affinity chromatography. On the other hand, mouse ascites collection was performed for mass production and purification of unicellular antibody against expressed malaria antigen. Female BALB / c mice of about 8 weeks were injected intraperitoneally with 200 μl of pristane (or Freund's incomplate adjuvant). 7 to 10 days after PBS (phosphate buffered saline) 5x10 ⁵ washed with - a 5x10 ⁶ of fused cells (hybridoma cells) were injected into the peritoneal cavity of mice. After a week or two, ascites began to kick into the abdominal cavity of the mouse, and the ascites was collected by puncturing the abdominal cavity with a 19G needle. The collected ascites was placed at 4 ° C. for at least 1 hour, followed by centrifugation at 5,000 × g for 15 minutes, and only the supernatant was carefully collected.

Antibody only was purified using Protein A column, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to investigate the molecular weight of the purified antibody. In addition, in order to confirm the response of the antibody to the antigen, an immunoblot was performed to confirm the reaction zone.

As a result, first, SDS-PAGE and Western blot were performed to observe whether monoclonal antibodies responded to the lysate of tropical fever malaria mesozoite, especially LDH. The total band pattern of the lysate was found to be approximately 9-11, of which 33 kDa band was found to be the LDH portion of tropical malaria.

In addition, Western blot was performed to confirm that each monoclonal antibody reacted with the febrile malaria LDH antigen. As shown in FIGS. 9 and 10, in all monoclonal antibodies against PfLDH # 2 and PfLDH # 3, There was a strong response at 33kDa indicating LDH.

Next, to investigate the sensitivity of monoclonal antibodies, the tropic malaria mesozoite lysate was diluted step by step and used in the experiment. All of the monoclonal antibodies against PfLDH # 2 were identified until the dilution of the tropic malaria mesozoite lysate at a concentration of 1.16 ng / ml, and all of the monoclonal antibodies against PfLDH # 3 were 1.22 ng / ml The reaction zone was confirmed until the lysate was diluted to a concentration of (see FIGS. 11 and 12).

As described above, the production of a monoclonal antibody that reacts with LDH (Lactate Dehydrogenase) of malaria according to the present invention and a high sensitivity malaria diagnosis method using the same can rapidly and efficiently diagnose malaria infection in large quantities. Provide diagnostic methods.

<110> Wonkwang University Center for Industry-Academy Cooperation <120> Monoclonal antibody and diagnostic method of malaria parasites <130> DIF / 06-02-18 / MR <160> 3 <170> KopatentIn 1.71 <210> 1 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Amino acid sequence of PfLDH # 1 <400> 1 Ser Lys Ala Lys Ile Val Leu Val Gly Ser Gly Met Ile Gly Gly Val   1 5 10 15 Met Ala Thr Leu Ile Val Gly Lys Asn Leu              20 25 <210> 2 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Amino acid sequence of PfLDH # 2 <400> 2 Phe Thr Lys Ala Pro Gly Lys Ser Asp Lys Glu Trp Asn Arg Asp Asp   1 5 10 15 Leu Leu Pro Leu Asn Asn Lys Ile Met Ile Glu Ile Gly Gly His              20 25 30 <210> 3 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Amino acid sequence of PfLDH # 3 <400> 3 Asp Tyr Gly His Ser Asp Ile Phe Gly Gly Thr Pro Val Val Leu Gly   1 5 10 15 Ala asn        

Claims (7)

1) preparing a peptide for the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 and attaching MAPs as a carrier thereto to immunize the peptide antigen with mice; 2) separating the serum having an absorbance of 0.8 or more from the immunized mice and performing cell fusion with myeloma cells; 3) selecting a hybrid cell (hybridoma cell) using HAT (hypoxantine, aminopterin, thymidine) medium from the fusion cell, and separating and culturing the antibody to confirm antibody secretion; 4) selecting monoclonal cell lines producing monoclonal antibodies from the hybrid cells using limiting dilution; 5) A method for producing a monoclonal antibody against malaria protozoa comprising culturing the monoclonal cell line in large quantities to purely isolate only a single cell population antibody using Protein A affinity chromatography. 1) preparing a peptide for the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 and attaching MAPs as a carrier thereto to immunize the peptide antigen with mice; 2) separating the serum having an absorbance of 0.8 or more from the immunized mice and performing cell fusion with myeloma cells; 3) selecting a hybrid cell (hybridoma cell) using HAT (hypoxantine, aminopterin, thymidine) medium from the fusion cell, and separating and culturing the antibody to confirm antibody secretion; 4) injecting mice with intraperitoneal pristane or incomplete freund's adjuvant (IFA) intraperitoneally and injecting the fused cells intraperitoneally 7-10 days later; 5) 1 to 2 weeks after the injection of the fusion cells, if the ascites fills the abdominal cavity, puncture the ascites with a needle, collect the centrifugal precipitate, and collect the supernatant; 6) A method for producing a monoclonal antibody against malaria protozoa comprising the step of purely separating the supernatant from the antibody using a Protein A column. delete delete delete The isotype of the monoclonal antibody according to claim 1 or 2, wherein the isotype of the monoclonal antibody against SEQ ID NO: 2 is the IgM class, the isotype of the monoclonal antibody against SEQ ID NO: 3. Is an IgG2b class. The method according to claim 1 or 2, wherein the malaria protozoa is Plasmodium falciparum or Plasmodium vivax .

Images